Tags

Type your tag names separated by a space and hit enter

HIV and HAART-Associated Dyslipidemia.

Abstract

Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS illness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia.This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Authors+Show Affiliations

    ,

    HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.

    Source

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    21643501

    Citation

    Feeney, Eoin R., and Patrick W G. Mallon. "HIV and HAART-Associated Dyslipidemia." The Open Cardiovascular Medicine Journal, vol. 5, 2011, pp. 49-63.
    Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J. 2011;5:49-63.
    Feeney, E. R., & Mallon, P. W. (2011). HIV and HAART-Associated Dyslipidemia. The Open Cardiovascular Medicine Journal, 5, pp. 49-63. doi:10.2174/1874192401105010049.
    Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J. 2011;5:49-63. PubMed PMID: 21643501.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - HIV and HAART-Associated Dyslipidemia. AU - Feeney,Eoin R, AU - Mallon,Patrick W G, Y1 - 2011/02/24/ PY - 2010/12/15/received PY - 2011/01/01/revised PY - 2011/01/06/accepted PY - 2011/6/7/entrez PY - 2011/6/7/pubmed PY - 2011/6/7/medline KW - HAART KW - HIV KW - cholesterol KW - dyslipidemia KW - lipids. KW - triglycerides SP - 49 EP - 63 JF - The open cardiovascular medicine journal JO - Open Cardiovasc Med J VL - 5 N2 - Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS illness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia.This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies. SN - 1874-1924 UR - https://www.unboundmedicine.com/medline/citation/21643501/full_citation L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21643501/ DB - PRIME DP - Unbound Medicine ER -